Skip to main content

Intralesional Corticosteroids

Intralesional corticosteroids — primarily triamcinolone acetonide — are used across urology as anti-inflammatory and anti-fibrotic adjuncts rather than stand-alone therapies. The most guideline-supported indications are submucosal injection for Hunner lesions in IC/BPS (AUA Grade C) and adjuncts to endoscopic management of urethral strictures and bladder-neck contractures. Other applications include genital lichen sclerosus / lichen planus, BXO at preputioplasty, vesicourethral anastomotic stenosis (VUAS) after RP, and ureteroenteric anastomotic strictures.[1][2][3]

For related agents, see High-potency topical corticosteroids, Topical calcineurin inhibitors, Antimitotics / antifibrotics (mitomycin C), Platelet-rich plasma, and Intravesical IC/BPS agents.

Mechanism in urologic fibrotic and inflammatory disease​

Triamcinolone acetonide acts through:[4][5]

  • Anti-inflammatory — phospholipase-A2 inhibition → reduced prostaglandins / leukotrienes; decreased capillary permeability and leukocyte migration
  • Anti-fibrotic — suppression of fibroblast proliferation and collagen synthesis; reduced MMP-3 and TGF-β expression in treated bladder-neck tissue[6]
  • Local immunomodulation with minimal systemic exposure when properly dosed

Injectable suspension 40 mg/mL (Kenalog) is the most commonly used formulation.[5]

IC/BPS — Hunner lesions (AUA-recommended)​

AUA IC/BPS guideline 2022 (Recommendation; Grade C): if Hunner lesions are present, fulguration with electrocautery and/or injection of triamcinolone should be performed.[3]

Technique​

Endoscopic submucosal injection of triamcinolone directly into and around Hunner lesions under cystoscopic guidance.[7]

Efficacy​

StudynFinding
Funaro 201836Pain VAS 8.3 → 3.8 (p < 0.001); 70% had sustained improvement at 12-mo follow-up[7]
Mateu 201720VAS 8 → 2.5 (p < 0.001) with lower-dose low-concentration technique[8]

Triamcinolone injection is one of the few IC/BPS therapies producing months-long improvement after a single procedure, though periodic retreatment is typically necessary.[3] See Intravesical IC/BPS agents for the broader instillation and injection framework.

Urethral stricture — adjunct to internal urethrotomy​

Intralesional corticosteroid is one of the most-studied adjuncts to internal urethrotomy (IU) / urethral dilation.

Meta-analytic evidence​

  • Pang 2021 systematic review and meta-analysis (26 studies) — any adjunct to minimally invasive stricture treatment lowered recurrence (OR 0.37; 95% CI 0.27–0.50; p < 0.001). Mitomycin C had the strongest signal (intralesional OR 0.23; 95% CI 0.11–0.48) — steroids remain an accepted adjunct, but MMC leads when available[9]
  • Zhang 2014 meta-analysis (8 RCTs, n = 203) — local steroids + IU prolonged time to recurrence (mean 10.14 vs 5.07 months; p < 0.001)[10]
  • Jacobs 2021 systematic review — the positive clinical effect of steroids appears to decrease with longer follow-up, suggesting a time-limited anti-fibrotic benefit[11]

Technique​

Triamcinolone acetonide 40 mg/mL injected submucosally at the stricture site at 4–8 points via cystoscopic injection needle, either at the time of urethrotomy or as a postoperative series.[12][13] The original Sharpe-Finney 1976 series (n = 96) established the technique and noted particular utility for distal / meatal strictures and post-RP anastomotic strictures.[12]

Agent comparison: mitomycin C has the strongest evidence among stricture adjuncts; intralesional corticosteroids are a reasonable alternative when MMC is unavailable or contraindicated. See Antimitotics / antifibrotics.[9]

Bladder-neck contracture and post-RP VUAS​

BNC after TURP / open prostatectomy and VUAS after radical prostatectomy both carry high recurrence rates after endoscopic treatment alone. Triamcinolone has emerged as a valuable adjunct.

Post-TURP BNC​

  • Zhang 2021 — 28 patients with highly recurrent BNC (mean recurrence interval 2.2 months) treated with transurethral resection + intra- and postoperative triamcinolone injections (40 mg/mL at 8 points, repeated q4 wk × 3) — 92.9% success at median 2.8-year follow-up[13]
  • Sun 2022 — 180-W GreenLight laser vaporization with repeated triamcinolone injections (n = 46) — zero recurrence during follow-up; significant improvement in Qmax, IPSS, QoL, PVR. Immunohistochemistry showed reduced collagen I, MMP-3, and TGF-β in treated tissue[6]

Post-RP VUAS​

  • Eltahawy 2008 — Holmium laser incision at 3 and 9 o'clock with triamcinolone at incision sites — 83% success (19/24) at mean 24-mo follow-up[14]
  • Kravchick 2013 — TRUS-guided injection of long-acting steroids into the scar area after dilation had the highest efficiency quotient among treatment modalities, with lower retreatment rates and no incontinence vs cold-knife urethrotomy or TUR[15]
  • Palminteri-Ferrari technique (Palminteri 2024) — Holmium laser incisions at 3-6-9-12 o'clock + triamcinolone 40 mg, repeated up to 3 times — 8.9% failure rate in 45 patients at 18-month follow-up[16]

Peyronie's disease — not recommended​

Intralesional corticosteroids have a long history but limited supporting evidence and are not recommended by current guidelines as a preferred intralesional agent.

  • AUA PD guideline 2015 — intralesional corticosteroids (dexamethasone, betamethasone + hyaluronidase + lidocaine) have been studied but have not consistently shown efficacy in placebo-controlled trials[17][4]
  • Rosenberg 2023 Cochrane review — very low certainty evidence for intralesional betamethasone vs saline; uncertain effects on curvature (RR 0.75; 95% CI 0.20–2.79; single small study, n = 30)[18]
  • Manfredi 2025 SR on acute-phase PD injection therapy — corticosteroids showed variable efficacy with favorable safety, but overall evidence quality is low[19]
  • Ure 2021 non-randomized methylprednisolone 40 mg weekly × 8 weeks (n = 48 acute-phase) — significant reductions in plaque size (13.6 → 10.8 mm; p = 0.025) and PDQ scores; no AEs[20]

Why not preferred​

  • Risk of tunical atrophy and local tissue thinning with repeated injection
  • Potential worsening of erectile function
  • Superior alternatives exist: collagenase clostridium histolyticum (stable disease 30–90°), interferon α-2b, and intralesional verapamil — all better supported by AUA / EAU / CUA / ISSM guideline consensus[18][21][22]

See Peyronie's disease agents for the broader PD intralesional comparison.

Genital lichen sclerosus and lichen planus​

ACOG Practice Bulletin 224 (Level C): intralesional corticosteroid injections for LS poorly controlled or resistant to topical corticosteroids.[2] Triamcinolone acetonide — no more than 40 mg total across the entire vulva — is standard.[23]

Intraurethral clobetasol for penile / urethral LS​

  • Potts 2016 — intraurethral clobetasol via catheter — 89% success avoiding urethroplasty at mean 24.8-mo follow-up[24]
  • Hayden 2020 — topical + intraurethral clobetasol improved AUASS 12 → 8 and QoL bother 4 → 2; 85.7% avoided surgery[25]

BXO in children — Wilkinson 2012​

Foreskin preputioplasty + intralesional triamcinolone — 81% fully retractile foreskin at 14-month follow-up, with significantly lower meatal stenosis rates (6% vs 19%) vs circumcision.[26] See High-potency topical corticosteroids for the first-line topical framework in LS.

Ureteroenteric anastomotic strictures​

Triamcinolone has been incorporated into endoscopic management of benign UEAS after urinary diversion.

  • Katims 2021 — 24 UEAS treated with laser incision + triamcinolone + balloon dilation to 24F + temporary stenting — 83.3% success at median 30-month follow-up[27]
  • Meretyk 1992 — early endoureterotomy experience suggested triamcinolone into the stricture bed favorably influenced subsequent ureteral patency[28]

Idiopathic bulbar urethritis​

Ashraf 2017 pilot (n = 14 boys with idiopathic bulbar urethritis — hematuria ± dysuria without infection) — cystoscopy-guided instillation of 40 mg triamcinolone — 85.7% complete or partial resolution, though 50% required at least one additional treatment.[29]

Dosing summary by indication​

IndicationTypical doseTechniqueFrequency
Hunner lesions (IC/BPS)Variable low-dose submucosalEndoscopic submucosal injection into / around lesionsSingle session; retreat PRN (~10–12 mo)[3][7][8]
Urethral stricture40 mg/mL at 4–8 pointsSubmucosal injection at urethrotomy siteAt IU ± postoperative series[9][12]
Bladder-neck contracture80 mg (2 mL of 40 mg/mL) at 8 pointsCystoscopic injection at incision sitesIntraop + q4 wk × 3 postop[13][6]
VUAS post-RP40 mg at incision sitesTransurethral or TRUS-guidedAt incision; repeat PRN[14][15][16]
Vulvar LS≤40 mg total across the vulvaIntralesional into plaquesPRN for refractory disease[2][23]
BXO — pediatricIntralesional at preputioplastyInjection into BXO-affected tissueAt time of preputioplasty[26]
Ureteroenteric strictureInto stricture bedAntegrade / ureteroscopic injectionAt laser incision[27]

Safety​

Generally well tolerated when dosed appropriately; complications are mild and localized in most series.

ConcernDetails
UTI2.9–14% with urethral steroid injection[9]
Bleeding8.8%
Extravasation5.8%
Iatrogenic Cushing's syndromeTwo pediatric cases reported after intralesional triamcinolone for urethral strictures — prompts use of shorter-acting triamcinolone diacetate in children at 4-week intervals with age-adjusted dosing[30]
Tissue atrophyTheoretical with repeated injection — particularly in tunica albuginea (PD) and thin genital skin[5]
Systemic steroid effectsImpaired wound healing, hyperglycemia, adrenal suppression with repeated high doses, immunosuppression[5]

Evidence Summary​

IndicationEvidence levelKey source
IC/BPS Hunner lesionsGuideline (AUA Grade C)Clemens 2022[3]; Funaro 2018[7]; Mateu 2017[8]
Urethral stricture adjunctLevel 1 (multiple meta)Pang 2021[9]; Zhang 2014[10]; Jacobs 2021[11]
Bladder-neck contractureLevel 3 (retrospective)Zhang 2021 92.9%[13]; Sun 2022 zero recurrence with IHC correlate[6]
VUAS post-RPLevel 3Eltahawy 2008[14]; Kravchick 2013[15]; Palminteri 2024[16]
Peyronie's diseaseVery low (Cochrane)Rosenberg 2023[18]; AUA 2015[17]
Vulvar LS / LP (refractory)Guideline (ACOG Level C)ACOG 224[2]
Penile / urethral LSLevel 3Potts 2016[24]; Hayden 2020[25]
Pediatric BXO at preputioplastyLevel 3Wilkinson 2012[26]
Ureteroenteric stricturesLevel 3Katims 2021[27]

Clinical Positioning​

  • Intralesional triamcinolone is adjunctive, not primary. Its strongest role is prolonging time to recurrence when layered on fulguration, internal urethrotomy, or endoscopic BNC / VUAS incision.[3][9][13]
  • For Hunner-lesion IC/BPS, fulguration + triamcinolone is AUA Grade C and one of the few IC/BPS therapies that produces months-long improvement after a single session. Retreatment PRN.[3][7]
  • For urethral stricture, mitomycin C has the strongest meta-analytic signal (Pang 2021 OR 0.23 vs 0.37 pooled adjuncts) — consider MMC first where available; triamcinolone remains a reasonable alternative.[9]
  • For recurrent BNC / VUAS, the combination of endoscopic incision + triamcinolone (intraop + scheduled postop q4 wk × 3) produces the best outcomes — Zhang 2021 reported 92.9% success in highly recurrent BNC and Sun 2022 reported zero recurrence with the GreenLight-plus-triamcinolone approach.[6][13]
  • Do not use intralesional corticosteroids as primary Peyronie's-disease therapy. Evidence is very low certainty, and CCH / interferon / verapamil are all better-supported across AUA / EAU / CUA / ISSM guidelines.[17][18][21]
  • For refractory genital LS, intralesional triamcinolone is ACOG Level C — ≤40 mg total across the vulva; reserve for disease unresponsive to topical clobetasol and calcineurin inhibitors.[2][23]
  • Pediatric BXO — preputioplasty + intralesional triamcinolone is a legitimate foreskin-preserving alternative to circumcision with lower meatal-stenosis rates (Wilkinson 2012).[26]
  • Iatrogenic Cushing's syndrome is a real pediatric risk — use shorter-acting triamcinolone diacetate with age-adjusted dosing and 4-week intervals.[30]
  • Document adjunct use — follow-up data suggest the positive clinical effect of steroid adjuncts attenuates over time; anticipate retreatment and surveil for recurrence beyond 12–24 months.[11]
  • Always maintain sterility and limit volume — UTI (up to 14%), minor bleeding (9%), and extravasation (6%) are the practical AE ceiling; watch for systemic absorption symptoms at cumulative dosing.[9]

See Also​

References​

1. Moreno G, Ramirez C, Corbalán J, et al. "Topical corticosteroids for treating phimosis in boys." Cochrane Database Syst Rev. 2024;1:CD008973. doi:10.1002/14651858.CD008973.pub3

2. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin No. 224." Obstet Gynecol. 2020;136(1):222–225. doi:10.1097/AOG.0000000000003945

3. Clemens JQ, Erickson DR, Varela NP, Lai HH. "Diagnosis and treatment of interstitial cystitis/bladder pain syndrome." J Urol. 2022;208(1):34–42. doi:10.1097/JU.0000000000002756

4. Trost LW, Gur S, Hellstrom WJ. "Pharmacological management of Peyronie's disease." Drugs. 2007;67(4):527–545. doi:10.2165/00003495-200767040-00004

5. US Food and Drug Administration. Triamcinolone acetonide — prescribing information. Updated 2025-04-15.

6. Sun X, Jin X, Leng K, Zhao Y, Zhang H. "180-W GreenLight laser photoselective vaporization with multiple triamcinolone acetonide injections for the treatment of bladder neck contractures." Lasers Med Sci. 2022;37(8):3115–3121. doi:10.1007/s10103-022-03568-2

7. Funaro MG, King AN, Stern JNH, Moldwin RM, Bahlani S. "Endoscopic injection of low dose triamcinolone: a simple, minimally invasive, and effective therapy for interstitial cystitis with Hunner lesions." Urology. 2018;118:25–29. doi:10.1016/j.urology.2018.03.037

8. Mateu L, Izquierdo L, Franco A, et al. "Pain relief after triamcinolone infiltration in patients with bladder pain syndrome with Hunner's ulcers." Int Urogynecol J. 2017;28(7):1027–1031. doi:10.1007/s00192-016-3213-3

9. Pang KH, Chapple CR, Chatters R, et al. "A systematic review and meta-analysis of adjuncts to minimally invasive treatment of urethral stricture in men." Eur Urol. 2021;80(4):467–479. doi:10.1016/j.eururo.2021.06.022

10. Zhang K, Qi E, Zhang Y, Sa Y, Fu Q. "Efficacy and safety of local steroids for urethra strictures: a systematic review and meta-analysis." J Endourol. 2014;28(8):962–968. doi:10.1089/end.2014.0090

11. Jacobs ME, de Kemp VF, Albersen M, de Kort LMO, de Graaf P. "The use of local therapy in preventing urethral strictures: a systematic review." PLoS One. 2021;16(10):e0258256. doi:10.1371/journal.pone.0258256

12. Sharpe JR, Finney RP. "Urethral strictures: treatment with intralesional steroids." J Urol. 1976;116(4):440–443. doi:10.1016/s0022-5347(17)58850-3

13. Zhang L, Liu S, Wu K, Mu X, Yang L. "Management of highly recurrent bladder neck contractures via transurethral resection combined with intra- and post-operative triamcinolone acetonide injections." World J Urol. 2021;39(2):527–532. doi:10.1007/s00345-020-03224-w

14. Eltahawy E, Gur U, Virasoro R, Schlossberg SM, Jordan GH. "Management of recurrent anastomotic stenosis following radical prostatectomy using Holmium laser and steroid injection." BJU Int. 2008;102(7):796–798. doi:10.1111/j.1464-410X.2008.07919.x

15. Kravchick S, Lobik L, Peled R, Cytron S. "Transrectal ultrasonography-guided injection of long-acting steroids in the treatment of recurrent / resistant anastomotic stenosis after radical prostatectomy." J Endourol. 2013;27(7):875–879. doi:10.1089/end.2012.0661

16. Palminteri E, Morselli S, Cindolo L, et al. "Iatrogenic or recurrent bladder neck contracture treated by the Palminteri-Ferrari technique: a new way to approach a frustrating condition." World J Urol. 2024;42(1):195. doi:10.1007/s00345-024-04912-7

17. Nehra A, Alterowitz R, Culkin DJ, et al. "Peyronie's disease: AUA guideline." J Urol. 2015;194(3):745–753. doi:10.1016/j.juro.2015.05.098

18. Rosenberg JE, Ergun O, Hwang EC, et al. "Non-surgical therapies for Peyronie's disease." Cochrane Database Syst Rev. 2023;7:CD012206. doi:10.1002/14651858.CD012206.pub2

19. Manfredi C, Russo GI, Capogrosso P, et al. "Injection therapy in the acute phase of Peyronie's disease: a systematic review of current evidence." J Sex Med. 2025;22(5):799–812. doi:10.1093/jsxmed/qdaf044

20. Ure I, Ozen A. "Intralesional low-dose methylprednisolone for the treatment of active-phase Peyronie's disease: a single-centre, preliminary prospective non-randomised study." Int J Clin Pract. 2021;75(3):e13754. doi:10.1111/ijcp.13754

21. Chierigo F, Fallara G, Tozzi M, et al. "Guideline of guidelines: Peyronie's disease." BJU Int. 2026;137(5):770–782. doi:10.1111/bju.70201

22. Manka MG, White LA, Yafi FA, et al. "Comparing and contrasting Peyronie's disease guidelines: points of consensus and deviation." J Sex Med. 2021;18(2):363–375. doi:10.1016/j.jsxm.2020.11.013

23. Ringel NE, Iglesia C. "Common benign chronic vulvar disorders." Am Fam Physician. 2020;102(9):550–557.

24. Potts BA, Belsante MJ, Peterson AC. "Intraurethral steroids are a safe and effective treatment for stricture disease in patients with biopsy-proven lichen sclerosus." J Urol. 2016;195(6):1790–1796. doi:10.1016/j.juro.2015.12.067

25. Hayden JP, Boysen WR, Peterson AC. "Medical management of penile and urethral lichen sclerosus with topical clobetasol improves long-term voiding symptoms and quality of life." J Urol. 2020;204(6):1290–1295. doi:10.1097/JU.0000000000001304

26. Wilkinson DJ, Lansdale N, Everitt LH, et al. "Foreskin preputioplasty and intralesional triamcinolone: a valid alternative to circumcision for balanitis xerotica obliterans." J Pediatr Surg. 2012;47(4):756–759. doi:10.1016/j.jpedsurg.2011.10.059

27. Katims AB, Edelblute BT, Tam AW, et al. "Long-term outcomes of laser incision and triamcinolone injection for the management of ureteroenteric anastomotic strictures." J Endourol. 2021;35(1):21–24. doi:10.1089/end.2020.0593

28. Meretyk S, Albala DM, Clayman RV, Denstedt JD, Kavoussi LR. "Endoureterotomy for treatment of ureteral strictures." J Urol. 1992;147(6):1502–1506. doi:10.1016/s0022-5347(17)37608-5

29. Ashraf J, Radford AR, Turner A, Subramaniam R. "Preliminary experience with instillation of triamcinolone acetonide into the urethra for idiopathic urethritis: a prospective pilot study." J Laparoendosc Adv Surg Tech A. 2017;27(11):1217–1221. doi:10.1089/lap.2017.0064

30. Augspurger RR, Wettlaufer JN. "Cushing's syndrome: complication of triamcinolone injection for urethral strictures in children." J Urol. 1980;123(6):932–933. doi:10.1016/s0022-5347(17)56200-x